文献速递前列腺增生与排尿功能障碍

衰弱、专科诊疗与社会人口学因素:美国医疗保险D部分受益人中膀胱过度活动症口服药物治疗类别利用的差异

Frailty, Specialized Care, and Sociodemographic Factors: Disparities in Oral Pharmacotherapy Class Utilization Among Medicare Part D Beneficiaries With Overactive Bladder in the United States.
PubMed 文献 · Urology · 2024-07-17

该回顾性队列研究利用2013-2018年医疗保险D部分20%处方索赔数据,分析111,761例接受口服药物治疗的膀胱过度活动症(OAB)受益人,发现衰弱状态、泌尿科或妇科处方医师及居住在美国南部与米拉贝隆利用可能性较高相关,而黑人和美国印第安人/阿拉斯加原住民患者利用米拉贝隆的可能性较低,提示治疗差异。

要点

  • 衰弱状态(OR 1.16)与米拉贝隆利用可能性较高相关。
  • 泌尿科(OR 2.05)或妇科(OR 1.74)处方医师与米拉贝隆利用可能性较高相关。
  • 黑人和美国印第安人/阿拉斯加原住民患者利用米拉贝隆的可能性低于白人受益人。

核心结论

  • 衰弱受益人和由泌尿科或妇科处方医师开具处方的受益人显示较高的β-3激动剂利用可能性。
  • 尽管进行了调整,黑人和美国印第安人/阿拉斯加原住民患者填写米拉贝隆处方的可能性较低,提示治疗差异。
  • 研究结果强调需要政策、干预和倡议以促进弱势人群中公平的OAB口服治疗利用。

研究设计与样本

  • 回顾性队列研究,利用2013-2018年医疗保险D部分20%研究可识别文件处方索赔数据集。
  • 使用基于索赔的衰弱指数(CFI)将≥65岁的OAB受益人分为非衰弱(CFI<0.15)、衰弱前期(0.15≤CFI<0.25)和衰弱(CFI>0.25)。
  • 采用逻辑回归模型评估衰弱与药物治疗利用之间的关联。
  • 共111,761例患者(占OAB队列的15.8%)接受口服药物治疗(抗胆碱能口服药物或米拉贝隆)。

主要发现

  • 接受口服药物治疗的患者中,71%为女性,83%为白人,11.9%为衰弱。
  • 控制年龄、共付额和双重资格状态后,衰弱状态(OR 1.16;95% CI [1.09-1.24])与米拉贝隆利用可能性较高相关。
  • 泌尿科(OR 2.05;95% CI [1.94-2.16])或妇科(OR 1.74;95% CI [1.6-1.9])处方医师与米拉贝隆利用可能性较高相关。
  • 居住在美国南部(OR 1.53;CI [1.49-1.61])与米拉贝隆利用可能性较高相关。
  • 黑人(OR 0.79;95% CI [0.74-0.85])和美国印第安人/阿拉斯加原住民(OR 0.54;95% CI [0.39-0.74])患者利用米拉贝隆的可能性低于白人受益人。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the prevalence of frailty among Medicare beneficiaries with overactive bladder (OAB), analyze oral therapy patterns, and examine potential disparities in treatment. METHODS: This retrospective cohort study utilized the 20% Research Identifiable File Medicare Part D prescription claims dataset (2013-2018). Using the Claims-Based Frailty Index (CFI), Medicare beneficiaries ≥65 years old with OAB were categorized as not frail (CFI <0.15), prefrail (0.15 ≤CFI<0.25), and frail (CFI >0.25). Logistic regression models assessed associations between frailty and pharmacotherapy utilization. RESULTS: Among 111,761 patients (15.8% of the OAB cohort) receiving oral pharmacotherapy (anticholinergic oral medications or mirabegron), 71% were women, 83% were White, and 11.9% were frail. After controlling for age, copayments and dual eligibility status, frail status (OR 1.16; 95% CI [1.09-1.24]), urology (OR 2.05; 95% CI [1.94-2.16]) or gynecology (OR 1.74; 95% CI [1.6-1.9]) prescribers and residing in the Southern United States (OR 1.53; CI [1.49-1.61]) were associated with higher likelihood of mirabegron utilization. Black (OR 0.79; 95% CI [0.74-0.85]) and American Indian/Alaska Native (OR 0.54; 95% CI [0.39-0.74]) patients were less likely to utilize Mirabegron than White beneficiaries. CONCLUSION: Frail beneficiaries and those with urology and gynecology prescribers showed higher likelihoods of beta-3 agonist utilization. Despite adjustments, Black and American Indian/Alaskan Native patients were less likely to fill mirabegron prescriptions, suggesting disparities in treatment. Our findings highlight the need for policies, interventions, and initiatives to promote equitable OAB oral therapy utilization in vulnerable populations.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Enemchukwu EA, Sinclair S, Mohamud H, et al. Frailty, Specialized Care, and Sociodemographic Factors: Disparities in Oral Pharmacotherapy Class Utilization Among Medicare Part D Beneficiaries With Overactive Bladder in the United States. Urology. 2024. PMID: 39029804. doi:10.1016/j.urology.2024.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。